EA201690844A1 - Ингибиторы gsk-3 - Google Patents

Ингибиторы gsk-3

Info

Publication number
EA201690844A1
EA201690844A1 EA201690844A EA201690844A EA201690844A1 EA 201690844 A1 EA201690844 A1 EA 201690844A1 EA 201690844 A EA201690844 A EA 201690844A EA 201690844 A EA201690844 A EA 201690844A EA 201690844 A1 EA201690844 A1 EA 201690844A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gsk
inhibitors
compounds
salts
compositions
Prior art date
Application number
EA201690844A
Other languages
English (en)
Inventor
Гуанлинь Ло
Лин Чэнь
Джин М. Дубовчик
Свони Е. Якутэн-Портэ
Вивекананда М. Врудхула
Сэньлян Пань
Прасанна Сивапракасам
Джон Е. Макор
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201690844A1 publication Critical patent/EA201690844A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Настоящее изобретение в целом относится к соединениям формулы I, включая их соли, а также композициям и способам применения соединений для лечения расстройств, связанных с GSK-3.
EA201690844A 2013-11-06 2014-11-03 Ингибиторы gsk-3 EA201690844A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900465P 2013-11-06 2013-11-06
PCT/US2014/063691 WO2015069594A1 (en) 2013-11-06 2014-11-03 Gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
EA201690844A1 true EA201690844A1 (ru) 2016-08-31

Family

ID=51982762

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690844A EA201690844A1 (ru) 2013-11-06 2014-11-03 Ингибиторы gsk-3

Country Status (12)

Country Link
US (1) US9718804B2 (ru)
EP (1) EP3066093B9 (ru)
JP (1) JP2016535755A (ru)
KR (1) KR102339227B1 (ru)
CN (1) CN105849098A (ru)
AU (1) AU2014347027A1 (ru)
CA (1) CA2929528A1 (ru)
EA (1) EA201690844A1 (ru)
IL (1) IL245442A0 (ru)
MX (1) MX2016005760A (ru)
SG (1) SG11201603209XA (ru)
WO (1) WO2015069594A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102292433B1 (ko) 2013-11-06 2021-08-20 브리스톨-마이어스 스큅 컴퍼니 Gsk-3 억제제로서 유용한 치환된 피리딘 유도체
EP3532465B1 (en) * 2016-10-26 2023-03-01 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
MA46889A (fr) * 2016-11-28 2019-10-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
US11053258B2 (en) 2016-11-28 2021-07-06 Bristol-Myers Squibb Company Pyrimidine carboxamides as GSK-3 inhibitors
ES2896938T3 (es) 2016-11-28 2022-02-28 Bristol Myers Squibb Co Inhibidores de GSK-3
JP7144863B2 (ja) 2016-12-28 2022-09-30 ミノリックス セラピューティクス エセ．エレ． イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
WO2018183122A1 (en) * 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
AU2018329840A1 (en) * 2017-09-07 2020-03-19 Augusta University Research Institute, Inc. Specific Akt3 activator and uses thereof
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2020132649A1 (en) * 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CA3147451A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
BRPI0414266A (pt) 2003-09-19 2006-11-07 Hoffmann La Roche derivados de tiazolopiridina como ligandos receptores da adenosina
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
US20080146536A1 (en) 2005-08-16 2008-06-19 Pharmacopeia, Inc. 2-Aminoimidazopyridines for treating neurodegenerative diseases
KR20100042643A (ko) 2007-07-09 2010-04-26 아스트라제네카 아베 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체
JP2011513253A (ja) 2008-02-27 2011-04-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病を治療するためのカルボキサミド−ヘテロアリール誘導体
CN102336720B (zh) 2011-03-02 2016-01-13 华中科技大学 2-氨基噻唑衍生物及制备方法和应用
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
KR102292433B1 (ko) 2013-11-06 2021-08-20 브리스톨-마이어스 스큅 컴퍼니 Gsk-3 억제제로서 유용한 치환된 피리딘 유도체

Also Published As

Publication number Publication date
EP3066093B9 (en) 2018-02-07
IL245442A0 (en) 2016-06-30
SG11201603209XA (en) 2016-05-30
JP2016535755A (ja) 2016-11-17
KR102339227B1 (ko) 2021-12-13
MX2016005760A (es) 2016-07-18
AU2014347027A1 (en) 2016-06-23
KR20160078494A (ko) 2016-07-04
CA2929528A1 (en) 2015-05-14
EP3066093A1 (en) 2016-09-14
US9718804B2 (en) 2017-08-01
WO2015069594A1 (en) 2015-05-14
EP3066093B1 (en) 2017-10-04
US20160272621A1 (en) 2016-09-22
CN105849098A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
EA201690844A1 (ru) Ингибиторы gsk-3
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201690087A1 (ru) Новые квиназолиноны как ингибиторы бромодомена
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201891501A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
EA201491970A1 (ru) Циклические мостиковые простые эфиры в качестве ингибиторов dgat1
EA201500931A1 (ru) Производные пиридин-4-ила